Marie Bosslett, Assistant Editor

At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.

Miiskin is transforming dermatologic care through telehealth, enhancing access, efficiency, and patient relationships, according to Ryan Trowbridge, MD, MS, MA, FAAD.

In case you missed it, this week we had news about the FDA's RPD Designation of QRX003 for Netherton Syndrome, Galderma's 2 new clinical trials of nemolizumab, Allergan Aesthetics' sPMA for SKINVIVE by Juvéderm, and more.

Robin Smith, MD, MBA, discusses the future of regenerative aesthetics and her exosome-based skin care and hair care brand, Exoceuticals.

A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multitarget therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.

Robin Smith, MD, MBA, champions exosome-powered skincare for long-lasting skin health and personalized regenerative aesthetics solutions for patients.

Discover how Robin Smith, MD, MBA, revolutionizes skin care with Exoceuticals, harnessing exosomes for advanced regenerative aesthetics and skin health solutions.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of July.

Learn more about the in-depth topics covered in the June 2025 print issue of Dermatology Times.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA's RPD Designation and showing promising clinical results.

Nektar Therapeutics reveals positive results from the REZOLVE-AD study, showcasing rezpegaldesleukin's efficacy in treating moderate to severe AD.

Almirall showcased groundbreaking research on atopic dermatitis, psoriasis, and actinic keratosis at the 2025 ICD.

Galderma launches clinical trials for nemolizumab, targeting systemic sclerosis and chronic pruritus of unknown origin, addressing critical patient needs.

Abeona Therapeutics' VIITAL trial reveals promising results for RDEB treatment, showcasing significant wound healing and pain relief with Zevaskyn therapy.

Arcutis Biotherapeutics' roflumilast cream 0.15% gains strong AAD endorsement for effective AD management in adults and children.

Sonia Batra, MD, shares effective summer acne solutions using lasers such as Aerolase Neo Elite and AviClear, ensuring tailored care for optimal skin health.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore insights on benzoyl peroxide and benzene risks in acne treatment from experts Renata Block, DMSc, MMS, PA-C, and John Barbieri, MD, MBA.

Discover the latest advancements in vitiligo treatment and awareness as Dermatology Times highlights this year's progress during Vitiligo Awareness Month.

Sonia Batra, MD, dispels common myths and shares expert tips on summer skin care for acne, emphasizing sun protection and tailored regimens.

Explore innovative strategies for managing chronic hand eczema, focusing on personalized care, early treatment, and understanding complex subtypes for better outcomes.

Renata Block, DMSc, MMS, PA-C, speaks with Adam Friedman, MD, FAAD, on innovative teledermatology initiatives in Washington, DC, addressing health care disparities and enhancing community access.

Iris Rubin, MD, highlights SEEN's science-backed hair care, designed for acne-prone skin, improving scalp health and reducing irritation.

Iris Rubin, MD, reveals how her brand SEEN transforms hair products to combat acne, promoting clearer skin through innovative, skin-friendly formulations.

In case you missed it, this week we had news about the FDA approval of dupilumab for bullous pemphigoid, the upcoming INTEGUMENT-INFANT trial for roflumilast, nail trends that challenge clinical diagnosis, and more.

A global survey reveals the significant psychosocial and financial burdens of hidradenitis suppurativa, highlighting the need for improved patient care and treatment options.

Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.

The VALIANT survey uncovers alarming depression rates in vitiligo patients, highlighting the urgent need for improved mental health screenings and interventions.

A real-world study shows the effectiveness of upadacitinib and abrocitinib for moderate to severe atopic dermatitis after 52 weeks of treatment.